414 M. S. Fineman et al. arm and 43 subjects (69.4%) in the exenatide-primed arm] and TZDs [9 subjects (14.8%) in the exenatide-naive arm and 10 subjects (16.1%) in the exenatide-primed arm]. Other medications commonly used during the study were ACE-inhibitors (16 in each arm), analgesics (14 in the exenatide-naive arm and 19 in the exenatide-primedarm), antithrombotic agents (16 in the exenatide-naive arm and 13 in the exenatide-primed arm), and serum lipid reducing agents (18 in the exenatide-naive arm and20 in the exenatide-primed arm). Clinical outcomes There was a statistically signiÔ¨Åcant difference betweentreatment arms in the proportion of subjects experiencing severe nausea, nausea leading to withdrawal, or vomiting b yt h ed a t eo ft h el a s td o s e( p=0.0018). As shown in Figure 1A, 34 subjects (55.7%) in the exenatide- naive arm and 17 subjects (27.4%) in the exenatide-primed arm experienced adverse events in this category.